Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Kicks Off Effort On Globulin, Other COVID-19 Therapies

But China Plasma Collections Challenging

Executive Summary

Japan's largest pharma firm has joined the global fray to develop potential therapies for the spreading coronavirus outbreak, focusing initially on its plasma products expertise. But this approach has had some challenges in China.

You may also be interested in...



Takeda Vaccines Head: Peer Review Process For COVID-19 Vaccines Must Be 'Very Open'

The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.

Coronavirus Update: EU Regulator Skeptical On Vaccine This Year, Takeda Prepares Hyperimmune Alliance

EMA leader doesn't share Oxford's optimism, Takeda-led alliance forges ahead with plasma-derived therapy plans, Indian pharma firm Cadila gets into testing kits.

Takeda Forecasts Tripling In Reported Op Profit Despite Virus Uncertainties

While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel